Protalix BioTherapeutics Inc (PLX)
1.69
+0.03
(+1.81%)
USD |
NYAM |
Nov 22, 16:00
1.70
+0.01
(+0.59%)
After-Hours: 20:00
Protalix BioTherapeutics Cash from Financing (Quarterly): -20.42M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -20.42M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 10.43M |
| March 31, 2023 | 14.23M |
| December 31, 2022 | 4.075M |
| September 30, 2022 | 1.52M |
| June 30, 2022 | 2.643M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -4.046M |
| September 30, 2021 | -25.99M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 42.11M |
| December 31, 2020 | 4.652M |
| September 30, 2020 | 4.472M |
| June 30, 2020 | -1.264M |
| March 31, 2020 | 38.61M |
| December 31, 2019 | |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2018 | -4.752M |
| March 31, 2018 | |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 9.542M |
| June 30, 2017 | -4.235M |
| March 31, 2017 | -6.726M |
| December 31, 2016 | 19.70M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | |
| December 31, 2015 | 6.101M |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.534M |
| March 31, 2015 | |
| December 31, 2014 | 0.003M |
| September 30, 2014 | 0.012M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.031M |
| December 31, 2013 | -0.068M |
| September 30, 2013 | 66.93M |
| June 30, 2013 | 0.03M |
| March 31, 2013 | |
| December 31, 2012 | 0.134M |
| September 30, 2012 | -0.14M |
| June 30, 2012 | 0.99M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-25.99M
Minimum
Sep 2021
42.11M
Maximum
Mar 2021
3.738M
Average
--
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Accuray Inc | -2.173M |
| Aethlon Medical Inc | -0.0038M |
| AIM ImmunoTech Inc | 0.137M |
| Perspective Therapeutics Inc | 0.628M |
| Armata Pharmaceuticals Inc | -0.061M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.105M |
| Cash from Investing (Quarterly) | 20.33M |
| Free Cash Flow | 7.171M |
| Free Cash Flow Per Share (Quarterly) | 0.0495 |
| Free Cash Flow to Equity (Quarterly) | 24.44M |
| Free Cash Flow to Firm (Quarterly) | 4.143M |
| Free Cash Flow Yield | 5.40% |